#nsclc

[mdnewsline1]

Major Breakthrough: Pembrolizumab Shows 5-Year Survival Benefit in NSCLC Patients!

Discover the groundbreaking real-world study on Pembrolizumab for non-small cell lung cancer (NSCLC)! 📊 With a 5-year survival rate of 26.9%, this treatment is changing the game for NSCLC patients. Learn how factors like PD-L1 expression, age, and ECOG-PS impact survival. Read the full analysis now! 🏥🔬

 Read the full study now: https://mdnewsline.com/five-year-survival-in-nsclc-patients-treated-with-first-line-pembrolizumab/

For more insights visit: https://mdnewsline.com/

[healthcaretechnologynews]

Biomarker driven segments of NSCLC - Yet to saturate with new approvals

Industry experts think that NSCLC space is rushed with so many approvals, yet it is a hot space for researchers, as NSCLC market has huge potential and even 1% market share is a piece of hot cake for the investors.

Currently, there are a total of 5 FDA-approved TKIs for frontline treatment in EGFR- positive NSCLC.

Though, recent data on frontline Osimertinib confers the greatest progression-free survival (PFS) advantage for patients with EGFR-positive non–small cell lung cancer (NSCLC)

Experts indicated that they would look forward to the novel approaches that are trying to enhance the activity of Osimertinib by targeting other oncogenic pathways in combination with anti-EGFR therapy.

Write to us at enquire@grgonline.com to learn how GRG Health is helping clients gather more in-depth market-level information on such topics.

Chemotherapy is backbone to treat many types of cancers, and research continues to find new chemotherapy regimens in combination with novel drugs. Over a decade, NSCLC space has evolved immensely.

Even though NSCLC space has been bifurcated into many biomarkers driven patients’ segment with specific approval in these segments, still in upcoming years we will see more approvals in the space. Industry experts think that this space is rushed with so many drugs, yet it is a hot space for researchers, as NSCLC is a huge market and even a single percent market share is a piece of hot cake for the investors.

Currently there are a total of 5 FDA-approved TKIs for frontline treatment of EGFR- positive NSCLC. These include erlotinib (Tarceva), gefitinib (Iressa), afatinib (Gilotrif), Dacomitinib (Vizimpro), and Osimertinib (Tagrisso).

We have seen a lot of exciting data over the past couple years with regard to these agents as monotherapy or in combination. Despite the sequential efficacy of these FDA-approved EGFR TKIs, frontline Osimertinib confers the greatest progression-free survival (PFS) advantage for patients with EGFR-positive non–small cell lung cancer (NSCLC) recently.

Therefore, we still expect to see several studies moving forward with results reported out in the coming years. We expect an emergence of new biomarker driven segments also (for e.g., Novel combinations, certainly targeting VEGF or MET).

There are exciting ongoing studies targeting MET following progression on Osimertinib. Experts indicated that they would look forward to the novel approaches that are trying to enhance the activity of Osimertinib by targeting other oncogenic pathways in combination with anti-EGFR therapy.

Visit our website now: https://www.grgonline.com/

[healthcareporium]

Innovating Lung Cancer Care: Antibody-Drug Conjugates Lead the Way

The ENHERTU Effect: A Closer Look at the Dynamic Duo Daiichi Sankyo and AstraZeneca Taking on HER2-mutant NSCLC Lung cancer remains one of the most challenging and prevalent forms of cancer. Within this landscape, innovative treatments are offering new hope. One such breakthrough is the collaboration between Daiichi Sankyo and AstraZeneca, which brings forth ENHERTU, an Antibody-Drug Conjugate…

[medsforcancer8]

buy non-small cell lung cancer

[andrewjhonson1234]

​Liquid biopsy is emerging as a transformative tool in oncology, offering a minimally invasive method to detect and monitor cancer through a simple blood test. In Italy, approximately 8,000 lung cancer patients annually are eligible for this procedure to determine optimal treatment strategies. Unlike traditional tissue biopsies that provide a static snapshot of the tumor, liquid biopsies enable real-time tracking of cancer progression by analyzing circulating tumor DNA (ctDNA). This approach enhances the personalization of therapy, particularly in cases like non-small cell lung cancer (NSCLC) where assessing EGFR gene mutations is crucial. Despite its advantages, challenges such as the potential for false negatives due to low ctDNA concentrations persist. Ongoing research aims to refine liquid biopsy techniques, expand their applications across various cancer types, and improve early detection methods. The integration of liquid biopsy into clinical practice underscores the importance of multidisciplinary collaboration and patient involvement in advancing precision oncology.

[butchlifeguard]

no way y'all aren't looking these up on the job

[industryexperts]

(via Global Lung Cancer Therapeutics Market | Trends, Forecast 2024-2030)

The lung cancer therapeutics market in 2024 is dominated by the non-small cell lung cancer (NSCLC) type, which holds an estimated 85.3% share due to its high prevalence and the development of targeted therapies and immunotherapies. These advancements specifically target genetic mutations such as EGFR, ALK, and ROS1, providing personalized treatment options and improving patient outcomes with immune checkpoint inhibitors like pembrolizumab and nivolumab. Conversely, the small cell lung cancer (SCLC) segment is anticipated to register the fastest CAGR of 11% during the forecast period 2024-2030, driven by increasing smoking rates and greater awareness of available treatments. While traditional SCLC therapies primarily consist of chemotherapy and radiotherapy, the introduction of new treatments like immune checkpoint inhibitors is beginning to improve survival rates, leading to a surge in global demand for lung cancer therapeutics.

[garnerbio]

PRESERVING THE PAST, DIAGNOSING THE FUTURE: FFPE BLOCKS IN CANCER TISSUE RESEARCH

FFPE tissue preservation involves two critical steps: fixation and embedding. The fixation process begins by immersing the tissue sample in formalin, a formaldehyde solution, which cross-links proteins and stabilizes cellular structures. This step is crucial as it prevents the degradation of tissue and preserves morphological details at the microscopic level

[perpetualseahorse]

Wtf tumblr

[futuretonext]

The Global Non-Small Cell Lung Cancer (NSCLC) Market is projected to grow at a CAGR of around 11.2% during the forecast period, i.e., 2022-27. Most of the market growth would be driven by the growing number of patients with Non-Small Cell Lung Cancer (NSCLC) type of lung cancer and the mounting demand for its effective diagnosis & treatment worldwide. 

[usnews23]

Perioperative Immunotherapy: A Promising Advancement in Early NSCLC Treatment

In recent years, the field of oncology has witnessed significant advancements in the treatment of various cancers, including non-small cell lung cancer (NSCLC). One such promising development is the utilization of perioperative immunotherapy, which has shown the potential in improving event-free survival (EFS) for early-stage NSCLC patients. In this comprehensive article, we explore the impact of…

[reasonsforhope]

"Doctors have begun trialling the world’s first mRNA lung cancer vaccine in patients, as experts hailed its “groundbreaking” potential to save thousands of lives.

Lung cancer is the world’s leading cause of cancer death, accounting for about 1.8m deaths every year. Survival rates in those with advanced forms of the disease, where tumours have spread, are particularly poor.

Now experts are testing a new jab that instructs the body to hunt down and kill cancer cells – then prevents them ever coming back. Known as BNT116 and made by BioNTech, the vaccine is designed to treat non-small cell lung cancer (NSCLC), the most common form of the disease.

The phase 1 clinical trial, the first human study of BNT116, has launched across 34 research sites in seven countries: the UK, US, Germany, Hungary, Poland, Spain and Turkey.

The UK has six sites, located in England and Wales, with the first UK patient to receive the vaccine having their initial dose on Tuesday [August 20, 2024].

Overall, about 130 patients – from early-stage before surgery or radiotherapy, to late-stage disease or recurrent cancer – will be enrolled to have the jab alongside immunotherapy. About 20 will be from the UK.

The jab uses messenger RNA (mRNA), similar to Covid-19 vaccines, and works by presenting the immune system with tumour markers from NSCLC to prime the body to fight cancer cells expressing these markers.

The aim is to strengthen a person’s immune response to cancer while leaving healthy cells untouched, unlike chemotherapy.

“We are now entering this very exciting new era of mRNA-based immunotherapy clinical trials to investigate the treatment of lung cancer,” said Prof Siow Ming Lee, a consultant medical oncologist at University College London hospitals NHS foundation trust (UCLH), which is leading the trial in the UK.

“It’s simple to deliver, and you can select specific antigens in the cancer cell, and then you target them. This technology is the next big phase of cancer treatment.”

Janusz Racz, 67, from London, was the first person to have the vaccine in the UK. He was diagnosed in May and soon after started chemotherapy and radiotherapy.

The scientist, who specialises in AI, said his profession inspired him to take part in the trial. “I am a scientist too, and I understand that the progress of science – especially in medicine – lies in people agreeing to be involved in such investigations,” he said...

“And also, I can be a part of the team that can provide proof of concept for this new methodology, and the faster it would be implemented across the world, more people will be saved.”

Racz received six consecutive injections five minutes apart over 30 minutes at the National Institute for Health Research UCLH Clinical Research Facility on Tuesday.

Each jab contained different RNA strands. He will get the vaccine every week for six consecutive weeks, and then every three weeks for 54 weeks.

Lee said: “We hope adding this additional treatment will stop the cancer coming back because a lot of time for lung cancer patients, even after surgery and radiation, it does come back.” ...

“We hope to go on to phase 2, phase 3, and then hope it becomes standard of care worldwide and saves lots of lung cancer patients.”

The Guardian revealed in May that thousands of patients in England were to be fast-tracked into groundbreaking trials of cancer vaccines in a revolutionary world-first NHS “matchmaking” scheme to save lives.

Under the scheme, patients who meet the eligibility criteria will gain access to clinical trials for the vaccines that experts say represent a new dawn in cancer treatment."

-via The Guardian, May 30, 2024

[mindblowingscience]

The mRNA revolution continues. Just a few years after mRNA vaccines proved their efficacy against COVID-19, scientists are now turning their attention to lung cancer. The mRNA vaccine, known as BTN116, developed by the German biotechnology company BioNTech, is the first of its kind and has entered phase 1 clinical trials in seven countries, including the United States and the United Kingdom. This vaccine is designed to treat non-small cell lung cancer (NSCLC), the most common form of the disease.

Continue Reading.

[nightunite]

pookie, do you know your job sounds so cool and interesting? what is your third favorite thing about it? also, hi pookie

Hi Pookie <3 For those unware: I am a histology data associate. Quick background: Histology=study of tissue. Anything that comes out of a person (and yes I mean ANYTHING and EVERYTHING; USE A FUCKING FLARED BASE AND ALSO LEARN GUN SAFETY YOU FUCKERS) via a hospital is kept at said hospital under federal guidelines for 10 years before they get rid of them. This tissue is fixed in formalin and kept in paraffin wax blocks (fluids are in tubes or smeared on slides if not spun down). These are called FFPE Blocks. We then acquire these blocks once they can be taken from the hospital, do tests/cut off sections of them, and sell the blocks/slides/images/etc to clients who use them for research and clinical trials. Biggest moneymaker as of right now is cancer, specifically Colorectal (CRC), Breast, and Non-Small Cell Lung Cancer (NSCLC). My job is reading through the pathology reports and assigning it a diagnosis in the system, followed by determining the stage of the cancer, adding any given test results run prior to us receiving it, whether or not the client has had treatment, and removing patient identifying info. I also compile this data to send out to clients when they order samples from us, including any 'special requests' such as if a person is bald, autopsy notes if it's from an autopsy, patient weight, etc. Lot of typing and reading and correcting people's fuck-ups. Third favorite thing? Probably the insane pathology reports I've gotten. All kinds of crazy shit that you get out of people. I'll post some of the weirder ones if someone asks.